A5380: A Phase II Trial of Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

- Age at least 18 years of age - With or without HIV. If living with HIV, on a stable antiretroviral regimen or untreated due to lack of indication per physician. - HIV RNA <50 and CD4 >100 - May not have Hepatitis B or C - Recently infected with HCV - Cannot be pregnant or breastfeeding - Must be willing to use birth control to prevent pregnancy - Must be willing to come to study visits - Must be able to swallow pills - May not have other known liver disease

Type of Study

Treatment

Locations

Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of Thomas Campbell,  MD

Thomas Campbell, MD

Study ID

Protocol Number: 20-0303

More information available at ClinicalTrials.gov: NCT04042740

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers